Carbon Ion Radiotherapy in the Management of the Tumors of the Peripheral Nervous System

Background/Aim: Malignant peripheral nerve sheaths tumors (MPNST) are rare, highly aggressive and radioresistant tumors of soft tissue. Carbon ion radiotherapy (CIRT) seems to be an attractive treatment option when surgery is not possible or refused by the patient. The aim of this study was to report our preliminary results (outcomes and toxicity) of CIRT in the treatment of MPNSTs. Patients and Methods: Our study retrospectively analyzed 13 patients (median age=54 years; range=23-72 years) with MPNST treated with CIRT for a median total dose of 73.6 Gy (relative biological effectiveness) (range=70.4-76.8 Gy) between 2013 and 2016. Results: Six local progressions were recorded, with a median local progression-free survival of 23.2 months (range=2.2-45.4 months). Acute toxicities were mild. Late toxicity of grade 2 or more was noted in two patients. Conclusion: CIRT yielded good local control with a low rate of acute and late toxicities.

[1]  N. Araki,et al.  Carbon ion radiotherapy for unresectable localized axial soft tissue sarcoma , 2018, Cancer medicine.

[2]  B. Feig,et al.  Malignant Peripheral Nerve Sheath Tumors: A Single Institution’s Experience Using Combined Surgery and Radiation Therapy , 2016, American journal of clinical oncology.

[3]  R. Orecchia,et al.  Dose prescription in carbon ion radiotherapy: How to compare two different RBE-weighted dose calculation systems. , 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[4]  J. Debus,et al.  Carbon Ion irradiation in the treatment of grossly incomplete or unresectable malignant peripheral nerve sheaths tumors: acute toxicity and preliminary outcome , 2015, Radiation Oncology.

[5]  Oliver Jäkel,et al.  Highly effective treatment of skull base chordoma with carbon ion irradiation using a raster scan technique in 155 patients: First long‐term results , 2014, Cancer.

[6]  A. Zietman,et al.  Promise and pitfalls of heavy-particle therapy. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  A. Tannapfel,et al.  Diagnosis, treatment and survival of 65 patients with malignant peripheral nerve sheath tumors. , 2014, Anticancer research.

[8]  J. Debus,et al.  Excellent local control with IOERT and postoperative EBRT in high grade extremity sarcoma: results from a subgroup analysis of a prospective trial , 2014, BMC Cancer.

[9]  Roberto Orecchia,et al.  Dose prescription in carbon ion radiotherapy: a planning study to compare NIRS and LEM approaches with a clinically-oriented strategy , 2012, Physics in medicine and biology.

[10]  C. H. Bush,et al.  Malignant peripheral nerve sheath tumor: Molecular pathogenesis and current management considerations , 2008, Journal of surgical oncology.

[11]  A. Ferrari,et al.  Pediatric malignant peripheral nerve sheath tumor: the Italian and German soft tissue sarcoma cooperative group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  T. Delaney,et al.  Results of radiation therapy for unresected soft-tissue sarcomas. , 2005, International journal of radiation oncology, biology, physics.

[13]  T. Loree,et al.  Malignant Peripheral Nerve Sheath Tumors of the Head and Neck: Analysis of Prognostic Factors , 2000, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[14]  B. Scheithauer,et al.  Malignant peripheral nerve sheath tumor: analysis of treatment outcome. , 1998, International journal of radiation oncology, biology, physics.